| | | | | | | | | | |
|
|
|
|
| Dockets Entered
On December 21, 2007
|
|
|
|
|
|
|
|
|
|
|
| Docket #
|
| Title
|
|
|
|
|
|
|
| 1997S-0163
|
| Dietary Supplements, Courtesy Letters (Letters of Objection)
|
|
|
|
|
| 2002V-0382
|
| Infrared Laser Aiming Devices
|
|
|
|
|
| 2006N-0168
|
| Food Labeling: Reference Daily Intakes & Daily Reference Values
|
|
|
|
|
| 2006V-0257
|
| Laser Light Show
|
|
|
|
|
| 2007D-0125
|
| Guidance for Industry: Evidence-Based Review System for the Scientific Evaluation of Health Claims
|
|
|
|
|
| 2007D-0396
|
| Drug-Induced Liver Injury: Premarketing Clinical Evaluation;Draft Guidance
|
|
|
|
|
| 2007N-0464
|
| Health Claims and Qualified Health Claims; Dietary Lipids and Cancer, Soy Protein and Coronary Heart Disease, Antioxidant Vitamins and Certain Cancers, and Selenium and Certain Cancers; Reevaluation;
|
|
|
|
|
|
|
|
|
| 2007P-0488
|
| Ensure that newly discovered CYP450 system phenotyping (metabolism) and inhibition information is appropriately incorporated into labeling for Felodipine Extended-Release Tablets USP (and other felodi
|
|
|
|
|
|
| 2007V-0490
|
| Laser Light Show
|
|
| |
|
| 1997S-0163
|
| Dietary Supplements, Courtesy Letters (Letters of Objection)
|
|
|
|
|
| LET 970
|
| Vasilios H. Frankos
|
| Vol #:
|
| 29
|
|
|
|
|
| LET 971
|
| Vasilios H. Frankos
|
| Vol #:
|
| 29
|
|
|
|
|
| LET 972
|
| Vasilios H. Frankos
|
| Vol #:
|
| 29
|
|
|
|
|
| LET 973
|
| Vasilios H. Frankos
|
| Vol #:
|
| 29
|
|
|
|
|
| LET 974
|
| Vasilios H. Frankos
|
| Vol #:
|
| 29
|
|
|
|
|
| LET 975
|
| Vasilios H. Frankos
|
| Vol #:
|
| 29
|
|
|
|
|
| LET 976
|
| Vasilios H. Frankos
|
| Vol #:
|
| 29
|
|
|
|
|
| LET 977
|
| Vasilios H. Frankos
|
| Vol #:
|
| 29
|
|
|
|
|
| LET 978
|
| Vasilios H. Frankos
|
| Vol #:
|
| 29
|
|
|
|
|
| LET 979
|
| Vasilios H. Frankos
|
| Vol #:
|
| 29
|
|
|
|
|
| LET 980
|
| Vasilios H. Frankos
|
| Vol #:
|
| 29
|
|
|
|
|
| LET 981
|
| Vasilios H. Frankos
|
| Vol #:
|
| 29
|
|
|
|
|
| 2002V-0382
|
| Infrared Laser Aiming Devices
|
|
|
|
|
| VRA 3
|
| Lynne L. Rice
|
| Vol #:
|
| 1
|
|
|
|
|
| 2006N-0168
|
| Food Labeling: Reference Daily Intakes & Daily Reference Values
|
|
|
|
|
| EXT 6
|
| American Heart Association
|
| Vol #:
|
| 1
|
|
|
|
|
| 2006V-0257
|
| Laser Light Show
|
|
|
|
|
| VRA 1
|
| Lynne L. Rice
|
| Vol #:
|
| 1
|
|
|
|
|
| 2007D-0125
|
| Guidance for Industry: Evidence-Based Review System for the Scientific Evaluation of Health Claims
|
|
|
|
|
| C 19
|
| American Herbal Products Association
|
| Vol #:
|
| 18
|
|
|
|
|
| 2007D-0396
|
| Drug-Induced Liver Injury: Premarketing Clinical Evaluation;Draft Guidance
|
|
| | | | | | | | |
|
| |
|
| C 3
|
| Novartis Pharmaceuticals Corporation
|
| Vol #:
|
| 1
|
|
|
|
|
| C 4
|
| Wyeth Pharmaceuticals, Inc.
|
| Vol #:
|
| 1
|
|
| |
|
| 2007N-0464
|
| Health Claims and Qualified Health Claims; Dietary Lipids and Cancer, Soy Protein and Coronary Heart Disease, Antioxidant Vitamins and Certain Cancers, and Selenium and Certain Cancers; Reevaluation;
|
|
|
|
|
|
|
|
|
|
|
| N 1
|
| FDA
|
| Vol #:
|
| 1
|
|
|
|
|
| 2007P-0488
|
| Ensure that newly discovered CYP450 system phenotyping (metabolism) and inhibition information is appropriately incorporated into labeling for Felodipine Extended-Release Tablets USP (and other felodi
|
|
|
|
|
|
| |
|
|
|
| ACK 1
|
| FDA/DDM to Mutual Pharmaceutical Company, Inc.
|
| Vol #:
|
| 1
|
|
|
|
|
| CP 1
|
| Mutual Pharmaceutical Company, Inc.
|
| Vol #:
|
| 1
|
|
|
|
|
| 2007V-0490
|
| Laser Light Show
|
|
|
|
|
| ACK 1
|
| FDA/DDM to KRP Music Work
|
| Vol #:
|
| 1
|
|
|
|
|
| VAR 1
|
| KRP Music Work
|
| Vol #:
|
| 1
|
|
